Stock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition

Stock Track

Nov 14, 2025

Shares of Cidara Therapeutics (CDTX) skyrocketed 13.63% in after-hours trading on Thursday, following reports that pharmaceutical giant Merck is nearing a deal to acquire the flu treatment start-up. The sudden surge in stock price comes as investors react to the potential for a significant premium in the acquisition.

According to the Financial Times, Merck is in advanced talks to purchase Cidara Therapeutics at a valuation that could exceed the company's current market capitalization of $3.3 billion. The report suggests that an official announcement of the deal could come as early as Friday, adding a sense of immediacy to the market's reaction.

This potential acquisition highlights Merck's interest in expanding its presence in the flu treatment market and recognizes the value of Cidara's innovative approaches. As investors await official confirmation, the stock is likely to remain volatile. If the deal materializes as reported, it could represent a significant windfall for Cidara shareholders and a strategic addition to Merck's pharmaceutical portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1143673185"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143673185\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143673185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143673185","market":"hk","top_or_hot":-1,"title":"Stock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition","media":"Stock Track","content":"<p>Shares of Cidara Therapeutics (CDTX) skyrocketed 13.63% in after-hours trading on Thursday, following reports that pharmaceutical giant Merck is nearing a deal to acquire the flu treatment start-up. The sudden surge in stock price comes as investors react to the potential for a significant premium in the acquisition.</p>\n\n<p>According to the Financial Times, Merck is in advanced talks to purchase Cidara Therapeutics at a valuation that could exceed the company's current market capitalization of $3.3 billion. The report suggests that an official announcement of the deal could come as early as Friday, adding a sense of immediacy to the market's reaction.</p>\n\n<p>This potential acquisition highlights Merck's interest in expanding its presence in the flu treatment market and recognizes the value of Cidara's innovative approaches. As investors await official confirmation, the stock is likely to remain volatile. If the deal materializes as reported, it could represent a significant windfall for Cidara shareholders and a strategic addition to Merck's pharmaceutical portfolio.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 07:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Cidara Therapeutics (CDTX) skyrocketed 13.63% in after-hours trading on Thursday, following reports that pharmaceutical giant Merck is nearing a deal to acquire the flu treatment start-up. The sudden surge in stock price comes as investors react to the potential for a significant premium in the acquisition.</p>\n\n<p>According to the Financial Times, Merck is in advanced talks to purchase Cidara Therapeutics at a valuation that could exceed the company's current market capitalization of $3.3 billion. The report suggests that an official announcement of the deal could come as early as Friday, adding a sense of immediacy to the market's reaction.</p>\n\n<p>This potential acquisition highlights Merck's interest in expanding its presence in the flu treatment market and recognizes the value of Cidara's innovative approaches. As investors await official confirmation, the stock is likely to remain volatile. If the deal materializes as reported, it could represent a significant windfall for Cidara shareholders and a strategic addition to Merck's pharmaceutical portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDTX","symbol_name":"Cidara Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1143673185","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143673185","pubTimestamp":1763076505,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Cidara Therapeutics (CDTX) skyrocketed 13.63% in after-hours trading on Thursday, following reports that pharmaceutical giant Merck is nearing a deal to acquire the flu treatment start-up....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDTX":"Cidara Therapeutics, Inc."},"translate_title":"个股追踪|Cidara Therapeutics盘后大涨13.63%因潜在收购默沙东","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDTX":1},"content_text":"Shares of Cidara Therapeutics (CDTX) skyrocketed 13.63% in after-hours trading on Thursday, following reports that pharmaceutical giant Merck is nearing a deal to acquire the flu treatment start-up. The sudden surge in stock price comes as investors react to the potential for a significant premium in the acquisition.\nAccording to the Financial Times, Merck is in advanced talks to purchase Cidara Therapeutics at a valuation that could exceed the company's current market capitalization of $3.3 billion. The report suggests that an official announcement of the deal could come as early as Friday, adding a sense of immediacy to the market's reaction.\nThis potential acquisition highlights Merck's interest in expanding its presence in the flu treatment market and recognizes the value of Cidara's innovative approaches. As investors await official confirmation, the stock is likely to remain volatile. If the deal materializes as reported, it could represent a significant windfall for Cidara shareholders and a strategic addition to Merck's pharmaceutical portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}